Arcturus Therapeutics Holdings Inc banner

Intrinsic Value

The intrinsic value of Arcturus Therapeutics Holdings Inc (ARCT) under the Base Case is 3.98 USD per share. Compared with the current market price of 8.36 USD, the stock appears Overvalued by 52% .

The intrinsic value is the average of valuations using the DCF method and multiples.

Do our valuations actually work? See backtest results .

ARCT Intrinsic Value
$3.98
Overvaluation 52%
Intrinsic Value
Price $8.36
Alert me when ARCT is below its intrinsic value
Today $3.18 · 62.0% below the current price

ARCT is valued in line with its history. A premium of this size has been typical over the past 5 years.

Alternatives to ARCT

Fundamental Analysis

What Arcturus Therapeutics Does

Biotechnology Health Care

Arcturus Therapeutics develops RNA medicines and vaccines. It designs messenger RNA and self-amplifying RNA drugs that tell the body’s cells to make a specific protein, then packages that RNA inside lipid nanoparticles so it can be delivered into the body. The company’s main work is in infectious disease vaccines and treatments for rare liver and genetic diseases.

Headquarters
United States of America US
Employees
106
IPO date
May 22, 2013
Read the full company overview
View Company Overview
Financials
Efficiency

Earnings Waterfall
Arcturus Therapeutics Holdings Inc

Wall St Price Targets

Shareholder Returns

Competitive Landscape

Ownership

ARCT Insider Trading
Buy and sell transactions by insiders

Continue ARCT Research

Decided on Arcturus Therapeutics Holdings? Get an email when ARCT reaches the price you’d buy at. Free with an account.

What is the Intrinsic Value of one ARCT stock?

The intrinsic value for Arcturus Therapeutics Holdings Inc (ARCT) under the Base Case is 3.98 USD.

Is ARCT stock undervalued or overvalued?

Compared with the current market price of 8.36 USD, the stock appears Overvalued by 52% .

How reliable are our estimates? See how past valuations played out
Back to Top